Drug intelligence / Profile preview

DW4421S-T0

Development stage: Unknown
Lead developer: Daewon Pharm
Modality: Small Molecules
Administration: Oral

Overview

**DW4421S-T0** is an oral tablet formulation of padoprazan, an investigational small-molecule potassium-competitive acid blocker developed in the DW4421 program. Padoprazan competitively and reversibly inhibits the gastric hydrogen/potassium-transporting ATPase proton pump at its potassium-binding site, suppressing the final step of gastric acid secretion. DW4421S-T0 is being evaluated in a Phase 1 multiple-ascending-dose study in healthy adults; the broader padoprazan program is being developed for gastroesophageal reflux disease, including erosive gastroesophageal reflux disease.

Targets

ATP4A (Potassium–transporting ATPase alpha chain 1)

Beyond the preview

Go deeper on DW4421S-T0.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DW4421S-T0.

Explore the full profile